Erratum
for
Testori et al., J Clin Oncol 26 (6) 955-962.
Journal of Clinical Oncology, Vol 26, No 22 (August 1), 2008: pp. 3819
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2008.18.8664
ERRATUM
The February 20, 2008, article by Testori et al entitled, "Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group" (J Clin Oncol 26:955-962, 2008) contained an error. The legend for Figure 4 did not include labels for figure parts A-E, and should have been:
Fig 4. Analyses of hazard ratios (HRs) between vitespen (1+ to 10+ vaccinations) and physician's choice (PC) arms (overall and by substage; based on a 150-day landmark analysis as in Fig 3). (A) M1a, (B) M1b, (C) M1a + M1b, (D) M1c, and (E) Overall. Each HR is indicated by a circle situated within its 95% CI (horizontal line). Intersecting vertical lines represent HRs of 1. HRs left of unity represent benefit by vitespen, and HRs right of unit represent benefit by PC.
The online version has been corrected in departure from the print.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
|
